Clearly miniscule in size, as to the behemoth that is Rahway, overall — and it is being conducted through Merck’s EU business development subsidiary — but this is a nice piece of bio-business validation, for smallish BioInvent.

The company is located near the southern seaward tip of Sweden, in Lund — and could see its financial future mightily enhanced if the combo trials go well, and it meets the ultimate primary endpoints, of overall survival — in various solid tumor cancers.

Here’s the bit, from The PharmaLetter:

…Swedish immuno-oncology specialist BioInvent International announced a clinical trial collaboration and supply agreement with MSD International Business GmbH, a subsidiary of Merck & Co. for a Phase I/IIa study of its monoclonal antibody BI-1910 in combination with the US pharma giant’s blockbuster cancer drug Keytruda (pembrolizumab)….

Now you know. Onward… and grinning, in spite of the lazily wheeling snowflakes, this morning. They aren’t sticking. Yet.

नमस्ते